EU member states concerned over drug information provisions in pharma package
This article was originally published in SRA
European Union member state ministers have welcomed the pharmacovigilance and anticounterfeiting proposals in the “pharmaceutical package” of draft legislation from the European Commission. However, they again expressed concerns about the proposal in the package to allow pharmaceutical companies to provide drug information directly to patients.
You may also be interested in...
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.